6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life

News
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 72

6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life

6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life

Background/Significance

Peer support programs offer care to women at-risk for and surviving breast cancer to improve their quality of life. This study evaluated a national, cancer-focused community-based organization’s (CBO) 1-on-1 and no-cost peer support program to identify its uptake and outcomes.

Materials and Methods

A secondary data analysis was conducted among 1054 women who contacted the CBO for information and support: patient-reported outcomes were assessed 30 days later. Associations between demographic and clinical characteristics and the offer, uptake, and outcomes of peer support were analyzed in a multivariable manner.

Results

In the evaluation sample of women, 49.2% were aged 46 to 64 years, 17.6% were non-White, 78.0% were mothers, and 88.2% were breast cancer survivors. Peer support was offered to 814 (76.7%) women, of whom 305 (37.5%) utilized it. Women offered peer support were younger (t = –2.86, df = 1050, P = .004), and reported higher CBO care (t = –4.57, df = 317, P <.001) and patient navigation quality (t = –3.64, df = 345, P <.001). Among those utilizing peer support, they were more likely to be mothers (χ² = 5.15, P <.05) and breast cancer-free (χ² = 4.24, P <.05), but experienced lower quality of life (t = 2.23, df = 800, P <.05). Among all women, barriers to utilizing peer support included time constraints (17.5%), feeling uncomfortable discussing personal issues (9.8%), and having concerns about peer support meeting their needs (5.7%). Positive outcomes among peer support users (M = 44.37/50, SD = 6.7) were associated with younger age (P <.10), and higher CBO care and parent navigation quality (both P <.001). In logistic regression modeling, the odds of being offered peer support were greater for younger women (OR, 1.26; 95% CI, 1.05-1.50) and those with higher CBO care quality (OR, 1.20; 95% CI, 1.08-1.32); the odds of utilizing peer support were greater for mothers (OR, 1.57; 95% CI, 1.10-2.24), those without a breast cancer diagnosis (OR, 1.59; 95% CI, 1.02-2.47), and lower quality of life (OR, 1.18; 95% CI, 1.02-1.37). In an age-adjusted model, higher-quality CBO care (B = 1.71, P <.001) and parent navigation quality (B = 0.58, P <.001) both contributed significantly to an enhanced peer support experience.

Conclusion

CBO-led peer support programs are well-received by women at risk for and diagnosed with breast cancer, and especially those who are younger and with lower quality of life. High-quality CBO care and parent navigation are important components of peer support as well, and barriers to utilizing peer support could be lowered to extend its reach and impact.

Articles in this issue

6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast
20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast
21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer
21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer
22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE
22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE
23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial
23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial
Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.